Chronic hepatitis B virus infection is a major risk factor for hepatocellular carcinoma (HCC). Hepatitis B virus X protein (HBx) is a hepatitis B virus protein that has multiple cellular functions, but its role in HCC pathogenesis has been controversial. Farnesoid X receptor (FXR) is a nuclear receptor with activities in anti-inflammation and inhibition of hepatocarcinogenesis. However, whether or how FXR can impact hepatitis B virus/HBx-induced hepatocarcinogenesis remains unclear. In this study, we showed that HBx can interact with FXR and function as a coactivator of FXR. Expression of HBx in vivo enhanced FXR-responsive gene regulation. HBx also increased the transcriptional activity of FXR in a luciferase reporter gene assay. The HBx-FXR interaction was confirmed by coimmunoprecipitation and glutathione S-transferase pull-down assays, and the FXR activation function 1 domain was mapped to bind to the third a helix in the C terminus of HBx. We also found that the C-terminally truncated variants of HBx, which were found in clinical HCC, were not effective at transactivating FXR. Interestingly, recruitment of the full-length HBx, but not the C-terminally truncated HBx, enhanced the binding of FXR to its response element. In vivo, FXR ablation markedly sensitized mice to HBx-induced hepatocarcinogenesis. Conclusions: We propose that transactivation of FXR by full-length HBx may represent a protective mechanism to inhibit HCC and that this inhibition may be compromised upon the appearance of Cterminally truncated HBx or when the expression and/or activity of FXR is decreased. (HEPATOLOGY 2017;65:893-906) 
H epatocellular carcinoma (HCC) is a deadly malignancy. (1, 2) Accumulating evidence suggests that hepatitis B virus (HBV) x protein (HBx), a 154-amino acid viral protein encoded by the HBV genome, plays an important role in the pathogenesis of HBV-associated HCC.
Early work showed that expression of HBx under the control of its own regulatory elements led to the development of HCC in transgenic mice. (3) Antibody to HBx (anti-HBx) can be detected in the serum or tissue samples of HCC patients. (4, 5) However, the oncogenic phenotype of HBx is not without controversies. A strain of independently generated ATX transgenic mice, in which expression of HBx was under the control of the human a 1 -antitrypsin Abbreviations: AF-1, activation function 1; anti-HBx, antibody to HBx; BSEP, bile salt export pump; CAR, constitutive androstane receptor; ChIP, chromatin immunoprecipitation; Cyp7a1, cytochrome P450 7A1; DBD, DNA-binding domain; EcRE, ecdysone receptor response element; EMSA, electrophoretic mobility shift assay; FXR, farnesoid X receptor; FXRE, FXR response element; GST, glutathione S-transferase; HA, hemagglutinin; HBV, hepatitis B virus; HBx, HBV X protein; HCC, hepatocellular carcinoma; LBD, ligand-binding domain; Luc, luciferase; LXR, liver X receptor; PBRE, phenobarbital response element; PPARc, peroxisome proliferator-activated receptor c; qPCR, real-time polymerase chain reaction; RT-PCR, semi-quantitative reverse transcription polymerase chain reaction; RXR, retinoid X receptor; SHP, small heterodimer partner; tk, thymidine kinase; WT, wild type.
gene promoter, failed to develop spontaneous HCC, (6) although they were more sensitive to diethylnitrosamine-induced carcinogenesis. (7, 8) HBx can be detected in both the cytoplasm and nucleus, and both populations contribute to the transcriptional regulation. Cytosolic HBx affects transcription by modulating cell signaling in the cytoplasm, whereas nuclear HBx can directly impact on chromatin and transcription. (2) As a transcriptional regulator, an intriguing feature of HBx is that it does not bind to DNA directly. Instead, HBx exerts its regulatory function mainly through protein-protein interactions. (2) The mechanism by which HBx may promote HCC remains poorly defined. Among the proposed mechanisms, HBx has been shown to induce oxidative stress in liver cells. (9) In addition to its carcinogenic activity, HBx can trigger inflammation, (10) an important pathogenic event associated with HCC. Interestingly, in addition to the full-length HBx protein, C-terminally truncated mutants of HBx have been reported in HCC patients, (11, 12) although the conclusions remain controversies. (13) The significance of the truncated HBx proteins in the pathogenesis of HCC remains to be defined.
Farnesoid X receptor (FXR) is a nuclear receptor highly expressed in the liver and intestine. FXR exhibits diverse functions, ranging from maintaining the homeostasis of bile acids (14) to regulating the metabolism of glucose and lipids, (15) inhibiting liver fibrosis, (16) promoting liver regeneration, (17) reducing liver inflammation, (18) and inhibiting hepatic (19, 20) and intestinal (21, 22) carcinogenesis. FXR -/-mice on a C57BL/6 background developed spontaneous liver tumors. (19) FXR inhibited nuclear factorjB-mediated inflammation, (18) which may have contributed to the antihepatocarcinogenic activity of FXR. In addition to FXR, the FXR target gene small heterodimer partner (SHP) has been proposed as a tumor suppressor gene that inhibits cellular proliferation, activates apoptosis, and suppresses cell migration. (23) (24) (25) (26) Knowing that HBx and FXR have opposite roles in the pathogenesis of HCC and that their effect on inflammation might be a shared mechanism by which these two proteins impact hepatocarcinogenesis, we propose that there might be a functional crosstalk between HBx and FXR. In this study, we showed that HBx enhanced the transcriptional activity of FXR by interacting with FXR and functioning as an FXR coactivator. We also found that the C-terminally truncated HBx variants were not effective at coactivating FXR. Moreover, FXR ablation markedly sensitized mice to HBx-induced hepatocarcinogenesis in vivo.
Materials and Methods

ANIMALS
The ATX HBx transgenic (ATX) mice have been described. (6) FXR 2/2 mice were purchased from the Jackson Laboratory. ATX mice on an ICR background were bred with FXR 2/2 mice on a C57BL/6 background to generate ATX-FXR 2/2 mice. All strains of mice used for the tumorigenic studies are on a mixed background of ICR and C57BL/6. Male mice of 6-8 weeks of age were used for all experiments, except those used for the tumorigenesis observations, in which both male and female mice were used and they were sacrificed
at 15 months of age. All genetically engineered mice have been bred and maintained in house for at least 12 months before being used for the experiments. Mice were not fasted before sacrificing. All interventions and tissue harvesting were performed during the light cycle. Mice were housed at the University of Pittsburgh's Division of Laboratory Animal Resources on the Prolab Isopro RMH 3000 (5P76) diet from LabDiet (St. Louis, MO). Ventilated Caging System from Alternative Design (Siloam Springs, AZ) was used to house the animals. Nestlets were used for animal environmental enrichment. The use of mice in this study complied with all relevant federal guidelines and institutional policies.
Sex and age of mice (or other in vivo experimental models) for all the experiments; The genetic background(s) of the mice or other experimental in vivo models; For transgenic or genetic mouse models, whether the controls were sibling littermates or were purchased separately (if purchased separately, were the animals cohoused to minimize potential microbiome effects); Specifics of the animal diet composition; Whether mice were fasted (and for how long) or not before a challenge or assessment is carried out; Type of bedding, caging system, and enrichment used for housing the mice; and If interventions were done, were they done during the light or dark cycle.
EXPERIMENTAL APPROACHES
For details on hydrodynamic liver transfection, plasmids, cell culture, transient transfection and luciferase reporter gene assay, real-time polymerase chain reaction (qPCR), immunoprecipitation, western blotting, immunofluorescence and immunohistochemistry, glutathione S-transferase (GST) pull-down assay, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay, see Supporting Information.
STATISTICAL ANALYSIS
Experimental values are expressed as the mean 6 standard deviation. Statistics were analyzed by Student t tests or Fisher's exact test. P < 0.05 was considered statistically significant.
Results
EXPRESSION OF HBx IN THE MOUSE LIVER INDUCES THE EXPRESSION OF FXR TARGET GENES
To examine the functional crosstalk between HBx and FXR, we evaluated the expression of FXR target genes in ATX mice that express HBx in the liver. (6) Expression of the ATX transgene was confirmed at the messenger RNA and protein levels (Fig. 1A) . The amount of liver lysate required for the detection of HBx in ATX mice was similar to the amount of liver lysate needed for the detection of the woodchuck WHx protein, (27) indicating that the level of HBx in ATX mice is comparable to that observed in the woodchuck infection model. SHP and cytochrome P450 7a1 (Cyp7a1) are two genes known to be positively and negatively regulated by FXR, respectively. Compared to wild-type (WT) mice, the hepatic expression of SHP was increased and the expression of Cyp7a1 was decreased in ATX mice (Fig. 1B) . The transgene had little effect on the expression of FXR, constitutive androstane receptor (CAR), and the CAR target gene Cyp2b10 (Fig. 1C) .
The HBx-responsive regulation of FXR target genes was independently observed in WT mice whose livers were transiently transfected with the expression vector for HBx. In this experiment, WT mice were hydrodynamically transfected with HBx or the control vector before being treated with the vehicle or the FXR agonist GW4064. Expression of HBx in transfected livers was confirmed by RT-PCR (Fig. 1D) . Expression of HBx increased and decreased the basal expression of SHP and Cyp7a1, respectively (Fig. 1E) . Upon GW4064 treatment, the respective expression of SHP and Cyp7a1 was induced and decreased in both the vector-transfected and HBx-transfected groups. In GW4064-treated mice, the respective expression of SHP and Cyp7a1 in HBx-transfected mice was significantly higher and lower than their vector-transfected counterparts (Fig. 1E ). Transfection of HBx had little effect on the expression of Cyp2b10 (Fig. 1F ).
HBx AUGMENTS FXR-MEDIATED TRANSCRIPTIONAL ACTIVITY IN REPORTER GENE ASSAY
To determine whether HBx can increase the transcriptional activity of FXR, HepG2 cells were cotransfected with the FXR expression vector and the FXR responsive reporter gene thymidine kinaseecdysone receptor response element-luciferase (tkEcRE-Luc), in the absence or presence of HBx. Transfection of HBx alone had little effect on the reporter activity, consistent with the broadly activating, albeit weak, transcriptional transactivation ability of HBx. (28) However, HBx dramatically increased the GW4064 responsive reporter activation ( Fig.  2A) . Potentiation of the FXR-mediated transactivation by HBx was also observed when transfected cells were treated with the FXR activator chenodeoxycholic acid (Fig. 2B) . HBx potentiated GW4064-responsive reporter activity in a dose-dependent manner (Fig. 2C) . The HBx effect appeared to be FXRspecific because HBx had little effect on the activity of CAR in cells cotransfected with the CAR responsive reporter gene tk-phenobarbital response element (PBRE)-Luc (29) (Fig. 2D ).
HBx IS RECRUITED TO THE FXR TARGET GENE PROMOTER AND ENHANCES THE BINDING OF FXR TO ITS RESPONSE ELEMENT
Potentiation of FXR transcriptional activity by HBx suggested that HBx might be recruited to the FXR target gene promoter, which was tested by chromatin immunoprecipitation (ChIP) assay. Transfection of HBx into HepG2 cells increased the basal and GW4064-responsive expression of the SHP gene (Fig. 3A) . To determine whether HBx can be recruited to the FXR target gene promoters, FXR was transfected into HepG2 cells with or without cotransfection of Flag-HBx. Transfected cells were treated with vehicle or GW4064 before ChIP analysis using an anti-Flag antibody. Flag-HBx was recruited onto the FXR response element (FXRE) on the bile salt export pump (BSEP) and SHP gene promoters, and this recruitment was enhanced in cells treated with GW4064 (Fig. 3B) . Electrophoretic mobility shift assay (EMSA) showed that HBx alone was not able to bind to the prototypical IR1 type of FXRE, but the addition of HBx dose-dependently increased the FXR-retinoid X receptor (RXR) heterodimer binding to FXRE (Fig. 3C) . The enhancement of binding was FXR-specific because the addition of HBx cannot increase the binding of CAR-RXR heterodimer to the CAR-responsive PBRE (29) (Fig. 3D ). The enhancement of FXR's binding to its FXRE by HBx was also confirmed by ChIP assay (Fig. 3E ).
HBx INTERACTS WITH FXR, AND BOTH PROTEINS ARE COLOCALIZED IN THE NUCLEUS
To understand the coactivation of FXR by HBx, we first used a GST pull-down assay to determine whether HBx can interact with FXR. GST-HBx specifically interacted with 35 S-FXR, and this interaction was disrupted when unlabeled FXR protein was added to the reaction (Fig. 4A) . The HBx-FXR interaction was further confirmed by coimmunoprecipitation assay. In this experiment, plasmids encoding the full-length hemagglutinin (HA)-tagged FXR and Flag-HBx were transiently transfected into cells individually or in combination. After 24-hour treatment with vehicle or GW4064, cells were lysed and immunoprecipitated with an anti-Flag antibody, and the presence of FXR in the immunoprecipitate was detected by western blotting using an anti-HA antibody. The HBx-FXR interaction was detected when both proteins were transfected, but the interaction was not enhanced by GW4064 treatment (Fig. 4B) . Immunofluorescence analysis showed that HA-FXR and Flag-HBx were colocalized in the nucleus when both were transfected into HepG2 cells (Fig. 4C) . The colocalization of endogenous FXR and HBx was shown by immunohistochemistry on human HCC sections (Fig. 4D) . 
MAPPING THE INTERFACE OF FXR-HBx INTERACTION
We used a GST pull-down assay to map the FXRHBx interaction domains. The full-length HBx protein contains three a helixes (Fig. 5A) . To determine which a helixes were important for the interaction, we constructed GST fusion proteins containing individual a helixes or the full-length HBx (Fig. 5B) and tested their abilities to interact with 35 S-labeled fulllength FXR. We showed that the second and third a helixes, but not the first a helix, were capable of binding to FXR (Fig. 5C, right panel) . The use of the second and third a helixes to interact with FXR was in contrast to the case of RXR, in which the first a helix was used for interaction (Fig. 5C, left panel) , consistent with a previous report. (30) To examine the functional relevance of the FXR-interacting a helixes, we constructed two deletion mutants of HBx that lacked the second a helix (deletion of amino acids 73-100 or D73-100) or the third a helix (D100-120). Compared to the full-length HBx, D100-120 was largely ineffective at coactivating FXR, whereas D73-100 remained partially effective to coactivate FXR ( Fig. 5D) . These results suggested that the third a helix of HBx was most functionally relevant in transactivating FXR.
To map the domain of FXR that interacts with HBx, we constructed FXR fragments that contained either activation function 1 (AF-1) 1 DNA-binding domain (DBD) or ligand-binding domain (LBD), as outlined in Fig. 6A , and tested for their ability to interact with the full-length HBx using the GST pulldown assay. To our surprise, it was the AF-11DBD fragment (Fig. 6B, left panel) , instead of the LBD (Fig. 6B, middle panel) , of FXR that interacted with HBx. Further GST pull-down analysis showed that it was the AF-1, but not the DBD, that was responsible for the interaction with HBx (Fig. 6C) . We then used a coimmunoprecipitation assay to confirm the mapping. The AF-11DBD fragment coimmunoprecipitated with HBx (Fig. 6D) . Moreover, it was the AF-1, but not the DBD, of FXR that coimmunoprecipitated with HBX (Fig. 6E) . The LBD of FXR failed to interact with HBx in the coimmunoprecipitation assay (Fig. 6E) .
THE C-TERMINALLY TRUNCATED HBx PROTEINS ARE NOT EFFECTIVE AT TRANSACTIVATING FXR, AND HCC SHOWS PREFERENTIAL LOSS OF FULL-LENGTH HBx AND INCREASED EXPRESSION OF C-TERMINALLY TRUNCATED HBx
The C-terminally truncated HBx variants may be present in HCC patients, and these variants may play distinct roles in hepatocarcinogenesis. (12, 31) We constructed the C-terminally truncated HBx-C40 (deletion of the C-terminal 40 amino acids) (Fig. 7A) , a truncation similar to those reported in HCC patients. (11) Compared to full-length HBx, HBx-C40 was not effective at potentiating the transcriptional activity of FXR in reporter assay (Fig. 7B ) and failed to increase the binding and recruitment of FXR to FXRE as shown by EMSA (Fig. 7C) and ChIP (Fig. 7D) , respectively.
To support the notion that truncated HBx may contribute to hepatocarcinogenesis, we profiled the expression of full-length and C-terminally truncated HBx by RT-PCR in 20 cases of HBV-positive HCC tumor tissues and compared the expression to that in paired adjacent nontumor tissues. We observed a preferential Fig. S1 ). We also performed immunohistochemistry on HBV-positive HCC and adjacent nontumor tissues using two antibodies to HBx (anti-HBx): amino acids 50-88 and amino acids 139-154. Full-length HBx can be recognized by both antibodies, whereas the C-terminally truncated HBx can only be detected by anti-HBx (amino acids 50-88). Both antibodies were efficient at detecting HBx in nontumor tissues (Fig. 7E) . In tumor tissues, however, HBx was detected only by anti-HBx (amino acids 50-88) but not by anti-HBx (amino acids 139-154), suggesting loss of full-length HBx in the tumor tissues. The immunohistochemical results were consistent with a previous report. (31) When the expression of FXR in HCC was analyzed, we found that the expression of FXR within the tumor or nontumor tissues was not different between patients expressing exclusively the full-length HBx and those who express both the full-length and c-terminal truncated HBx (c-HBx) (Fig. 7F) . The expression of FXR was lower in tumor tissues compared to nontumor tissues in both cohorts of patients, consistent with a previous report. , ATX, and ATX-FXR 2/2 mice were sacrificed at 15 months of age and examined for spontaneous liver tumors. Approximately 50% of the ATX-FXR 2/2 mice developed grossly identifiable liver tumors at 15 months of age, whereas no tumors were found in WT, ATX, and FXR 2/2 mice (Fig. 8A,B) . Tumorigenesis in the ATX-FXR 2/2 mice was confirmed by hematoxylin and eosin staining and immunostaining for the cell proliferation marker Ki-67 (Fig. 8C) . The livers of many of the ATX-FXR 2/2 mice without grossly identifiable tumors exhibited preneoplastic features, such as steatosis, necrosis, and infiltration of inflammatory cells (Fig. 8D) . It is interesting to note that the incidence of tumor and preneoplastic lesions in female ATX-FXR 2/2 mice was significantly higher than in their male counterparts (Fig. 8E) . Consistent with the tumor incidence and the gender effect, we observed significantly increased expression of the proinflammatory genes for tumor necrosis factor-a and inducible nitric oxide synthase in ATX-FXR 2/2 mice when male and female mice were analyzed in combination (Fig. 8F) . Within the genotype of ATX-FXR 2/2 , expression of the tumor necrosis factor-a and inducible nitric oxide synthase genes was substantially higher in female than in male mice (Fig. 8F) .
Considering that SHP has been proposed to be a tumor suppressor gene, (23) we also profiled the expression of SHP along with Cyp7a1, CAR, and Cyp2b10. Expression of SHP was not increased in ATX-FXR 2/2 mice (Supporting Fig. S2A ), suggesting that the induction of SHP in ATX mice was FXR-dependent. Expression of Cyp7a1 was elevated in ATX-FXR 2/2 mice (Supporting Fig. S2B ), likely due to the dominating effect of FXR ablation on the expression of this gene. Although expression of CAR was not changed (Supporting Fig. S2C ), expression of Cyp2b10 was increased in both FXR 2/2 and ATX-FXR 2/2 mice (Supporting Fig. S2D ), which might have been caused by the accumulation of hepatic bile acids due to the loss of FXR. (33) To gain insight into the heightened carcinogenesis in ATX-FXR 2/2 mice, we profiled expression of the epithelial-mesenchymal transition genes for E-cadherin and Ncadherin and the extracellular matrix degradation genes for matrix metalloproteinase 13, tissue inhibitor of metalloproteinase 1, and vimentin that are known to be involved in hepatocarcinogenesis. Expression of E-cadherin was decreased in ATX mice regardless of the FXR genotype (Supporting Fig. S3A ), consistent with a previous report. (34) However, expression of N-cadherin was not affected (Supporting Fig. S3B) . Expression of the genes for matrix metalloproteinase 13 and tissue inhibitor of metalloproteinase 1 was increased in both FXR 2/2 and ATX-FXR 2/2 mice (Supporting Fig. S3C ), but the expression of vimentin was unchanged (Supporting Fig. S3D ).
We also measured the expression of genes that are involved in transforming growth factor-b signaling, cell cycle, and apoptosis. Expression of the genes for transforming growth factors b1 and b2 and their receptors was not affected (Supporting Fig. S4A ). Expression of cyclins D1 and E1 was not affected either (Supporting Fig. S4B ). Expression of Bcl-2 was increased in both FXR 2/2 and ATX-FXR 2/2 mice (Supporting Fig. S4C ).
Discussion
HBx is considered to be an important cofactor in HBV-associated HCC. (1, 3, 28) The HBx proteins are often stably expressed in hepatocytes and serum of HCC patients throughout the hepatocarcinogenesis from chronic HBV infection to the development of HCC.
Because HBx has been implicated in the pathogenesis of HCC, most of the previous work on HBx has been focused on its detrimental effects on liver cells, such as mitochondrial damage, oxidative injury, and inflammation. In the current study, we showed that HBx functions as a potent coactivator of FXR, a nuclear receptor recognized for its anti-inflammatory and antihepatocarcinogenic activities. HBx interacts with and increases the transcriptional activity of FXR. Moreover, FXR ablation sensitizes the carcinogenic activity of HBx in vivo. While no spontaneous tumors were found in ATX mice or FXR 2/2 mice, nearly half of the ATX-FXR 2/2 mice developed liver tumors at 15 months of age. The lack of spontaneous liver tumor in the ATX mice was consistent with a previous report. (6) Although FXR 2/2 mice in the C57BL/6 background developed spontaneous liver tumors by the age of 15 months, (19) we did not observe liver tumors in our cohort of FXR 2/2 mice that were maintained in the mixed background of ICR and C57BL/6, likely due to the differences in genetic background. Based on our observations, we propose that transactivation of FXR by HBx may represent a protective mechanism to inhibit inflammation and the subsequent carcinogenesis. The protective role of FXR in the context of HBV infection and HBx expression is consistent with the notion that viral infection per se is rarely oncogenic in hepatocarcinogenesis and a "second hit" may be necessary to manifest the oncogenic activity of HBV/HBx. The "second hit" may include decreased expression and/or activity of FXR, as well as the appearance of Cterminally truncated HBx that fails to transactivate FXR. Indeed, expression of FXR is markedly decreased in human HCC. (32) The anti-HCC effect of FXR may have also been contributed to by its target gene, SHP, which itself was proposed to be a tumor suppressor gene. (23) (24) (25) (26) The SHP induction observed in ATX mice was absent in ATX-FXR 2/2 mice, suggesting that the SHP induction in ATX mice was FXR-dependent and the loss of SHP induction may have also contributed to the increased hepatocarcinogenesis in ATX-FXR 2/2 mice. The possibility that activation of FXR by HBx may function as a protective response was also supported by our observation that the C-terminal truncation mutants of HBx lost their capacity to coactivate FXR. The C-terminally truncated HBx proteins have been suggested to be present in HCC patients, which may have played distinct roles in hepatocarcinogenesis, (11, 12, 31) although these conclusions are not without controversies. (13) We showed that the expression level of FXR was indistinguishable between HCC that expresses the fell-length HBx and HCC that expresses the truncated HBx. It is tempting for us to speculate that the C-terminally truncated HBx may facilitate hepatic carcinogenesis by failing to mount an FXRmediated protective response. In addition to its effect of anti-inflammation and anticarcinogenesis, activation of FXR by HBx may be beneficial by improving hepatic metabolism and preventing the deleterious effect of toxic metabolites, such as toxic bile acids that are known to increase HBV viral gene expression. (35) In addition to transactivating FXR, HBx has been shown to affect the transcriptional activity of nuclear receptors liver X receptor (LXR), peroxisome proliferator-activated receptor c (PPARc), and RXR. There were notable differences between FXR and other nuclear receptors in their mode of interactions as well as in the functional outcomes of their interactions with HBx. For example, we showed that HBx enhances the transcriptional activity of FXR through interacting with the AF-1 domain of FXR and that the second and third a helixes of HBx are important for the interaction. In contrast, HBx also coactivates LXR and PPARc, but the HBx-LXR and HBx-PPARc interactions were mediated by the LBD of LXR (36, 37) and the DBD of PPARc, (38) respectively. Functionally, HBx coactivates FXR, whereas the consequence of the PPARc-HBx interaction is inhibition of the transcriptional activity of PPARc. (38) HBx can also bind to the LBD of RXR, but the interaction interface was localized to the N-terminal first a helix of HBx. (30) RXR is the obligatory heterodimerization partner of FXR. Because HBx uses a distinct interface to interact with FXR and RXR, it would be interesting to know whether HBx can simultaneously bind to both FXR and RXR.
Epidemiological and animal studies have shown that males are more susceptible to HCC, the mechanism of which was suggested to be the stimulatory effect of androgens and the protective effect of estrogens. We were surprised to find that the incidence of liver tumors in the ATX-FXR 2/2 mice was higher in female than in male mice. Expression of proinflammatory genes was also higher in female ATX-FXR 2/2 mice than in their male counterparts. A potential explanation is that FXR is more protective in female mice, so FXR ablation in females showed a more dramatic sensitizing effect. Expression of estrogen receptor and androgen receptor was not affected in the ATX-FXR 2/2 mice (data not shown). The detailed mechanism for the genderspecific effect of FXR ablation in HBx-induced hepatocarcinogenesis remains to be understood. It will be interesting to know whether the association between HCC and decreased expression of FXR is more prominent in female patients.
In summary, we have uncovered a novel function of HBx in coactivating FXR. Our results suggest that coactivation of FXR by HBx may represent a protective mechanism to inhibit hepatocarcinogenesis. This protective mechanism may be compromised in patients who carry the C-terminally truncated HBx proteins or whose expression or activity of FXR is compromised.
